En historisk milstolpe har realiserats då AcuCort AB (”AcuCort” eller ”Bolaget”) har erhållit en för...
Redeye presents its preview for Devyser’s Q1 2024 report, which is due on May 8.
Q1 2024 profit before loan losses came in at DKK 70m, DKK 4m (6%) ahead of our estimate.
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest An...
Redeye comments on Raketech’s preliminary Q1-results which are lower than expected as the company ha...
Slutlig studiedesign närmar sig Medivir har fullt fokus på att ta fostrox framåt mot en registrering...
Redeye comments on Freemelt’s new order from UKAEA, which deepens Freemelt’s position within the fus...
Tallinna Sadam's y/y decline in total cargo volumes ended in Q1 after persisting for nine quarters.
Redeye endorses Optomed and AEYE Health’s FDA (510k) clearance of Aurora AEYE.
Q1'24 results due 7 May '24e-'26e EBIT up 0.8-1.6% due to FX 29-39% below historical NTM P/E and NTM...
Redeye reviews Medivir's fourth quarter report, which presented another improvement of median time t...
The company writes down EUR 6m receivable which will have a corresponding negative impact on the EBI...
Sales -10% vs. ABGSCe, but EBIT in line at SEK 0m New customer signings in NW&FT and GC&MP to grow s...
Loihde’s Q1 was a pleasant surprise, as we had expected a softer start to the year.
Suominen reports Q1 results on May 7. We see earnings recovering throughout this year towards a norm...
Kraftigt stigande bruttomarginal Nettoomsättningen ökade med 185% till 31,0 mkr (10,9).
Solteq’s Q1 results were slightly weaker than expected and revenue declined slightly y/y in comparab...
Aktieanalytiker Mathias Carlson intervjuar VD Torbjörn Saxmo efter publicerad Q1-rapport.
Net sales have declined for the last four quarters on a q/q basis but this trend could come to an en...